The aim of the study is to investigate the serum levels of adipokines-resistin and visfatin in patients with metabolic syndrome. A prospective study was performed, including 153 (103 female, 50 male) subjects with metabolic syndrome. Carbohydrate metabolism was estimated by oral glucose tolerance test with 75g of glucose. Of the subjects investigated, 40 were with normal glycaemic tolerance, 40 - with impaired fasting glycaemia, 28 - with impaired glucose tolerance and 45 - with newly diagnosed diabetes mellitus type 2. The results were compared to those in a control group of 20 subjects without findings indicating metabolic syndrome. The serum levels of resistin and visfatin were measured with an enzyme immunoassay method (ELISA, BioVendor Laboratory Medicine, Inc., Czech Republic). There were significant differences in body mass index, waist circumference, systolic blood pressure, plasma level of blood glucose and serum level of triglycerides between the examined subjects with metabolic syndrome, as compared with the control group. The amount of serum resistin in subjects with metabolic syndrome and newly diagnosed diabetes mellitus type 2 was significantly higher, as compared to the controls. Subjects with metabolic syndrome and pathological glucose tolerance-impaired fasting glycaemia, impaired glucose tolerance and newly diagnosed diabetes mellitus type 2 were found with a significantly higher serum level of visfatin, as compared to normal glucose tolerance and to the controls. Subjects with metabolic syndrome and pathological glucose tolerance-impaired fasting glucose, impaired glucose tolerance and newly diagnosed diabetes mellitus type 2 exhibited significantly changes in serum levels of adipokines-resistin and visfatin.
If the inline PDF is not rendering correctly, you can download the PDF file here.
1. Galik S, Oakhill J, Steinberg G. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129-39.
2. Karastegiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol. 2010;318(1-2):69-78.
3. Koleva D, Orbetzova M, Atanasova P. Adipose tissue hormones and appetite and body weight regulators in insulin resistance. Folia Med. 2013;55(11):25-32.
4. Deng Y, Scherer P. Adipokines as novel biomarkers and regulators of the metabolic syndrome. Ann N Y Acad Sci. 2010;1212:E1-E19. doi: 10.1111/j.1749-6632.2010.05875.x.
5. Dogru T, Sonmez A, Tasci I, Bozoglu E. Yilmaz MI, Gene H. at al. Plasma resistin levels in patients with newly diagnosed untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract. 2007;76 (1):2-7.
6. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol. 2007;156(2):279-84.
7. Utzschneider K, Carr D, Tong J, Wallace T, Hull R, Zrika S at al. Resistin is not associated with insulin sensitivity or metabolic syndrome in humans. Diabetologia. 2005;48(11):2330-3.
8. Fukuhura A, Matsuda M, Nishizawa M. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;5708(307):426-30.
9. Saddi-Rosa P, Olivera C, Giuffrida F, Reis A. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr. 2010; 26;2:21. doi: 10.1186/1758-5996-2-21.
10. Christov Vl, Gocheva N, Petkova M, Zaharieva S, Tankova Tz, Orbetzova M, et al. A consensus of the Bulgarian Institute Metabolic Syndrome. Nauka Endocrinologia. 2010;2:3-70. (in Bulgarian)
11. World Health Organization. Definition and diagnosis of Diabetes Mellitus and intermediate Hyperglycaemia. Report of WHO/IDF Consultation. Geneva, World Health Org. 2006.
12. Tota-Maharaj R, Defilippis A, Blumenthal R, Blaha M. A practical approach to the metabolic syndrome: review of current concepts and management. Curr Opin Cardiol. 2010;25(5):502-12.
13. Borissova A-M, Kovatcheva R, Shinkov A, Atanassova I, Vukov M, Aslanova N et al. Prevalence and features of the metabolic syndrome in unselected bulgarian population. Endocrinologia. 2007;2:68-77. (in Bulgarian)
14. Rayanova G, Ganeva S, Todorova K, Lukanov T, Gecheva S. Disorders of the carbohydrate metabolism in patients with metabolic syndrome. Endocrinologia. 2014;3:139-43. (in Bulgarian)
15. De Luis DA, Gonzalez SM, Conde R, Aller R, Izaola O, Primo D. lack of association of serum resistin levels with metabolic syndrome criteria in obese patients. Clin Biochem. 2012;44(16):1280-3.
16. Silha V, Kresk M, Skrha J, Sucharda P, Nyomba B, Murphy L. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol. 2003;149(4):331-5.
17. Ebtesam DL-S and Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res. 2013;18(1):12-29.
18. Rabe K, Lehrke M, Parhofer K, Broedi U. Adipokines and insulin resistance, Mol Med. 2008; 14 (11-12): 741-751.
19. Tan H, Zhong M, Gomg H, Wang S, Zhang Y, Zhang W. Increased serum visfatin in patients with metabolic syndrome. Clinical Endocrinology. 2008; 6(69):878-884.
20. Esteghamati A, Morteza A, Zandieh A, Jafari S, Rezaee M, Nakhjavani M. The value of visfatin in the prediction of metabolic syndrome: a multifactorial analysis. J Cardiovasc Tnansl Res. 2012;5(4):541-6.
21. Vasilescu R, Ifrim S, Trigoviste C. Relationship between plasma adipokines, inflammation, insulin resistance and subclinical atherosclerosis in newly diagnosed type 2 diabetes. Journal of Diabetes Mellitus. 2011;1(2):17-25.
22. Rasouli N, Kern P. Adipocytokines and metabolic complications of obesity. J Clin Endocrinol Metab. 2008;93(11):S64-S73.